千红制药：公司正有序推进方圆制药的重整投资项目，目前正处于等待法院裁定过程中

Group 1 - The company is progressing with the restructuring investment project of Fangyuan Pharmaceutical and is currently awaiting a court ruling [2] - The company is actively planning the market promotion of Sulbactam-ampicillin and has included it in the 2025 business management plan and marketing outline [2] - The company is systematically advancing the marketing efforts for Sulbactam-ampicillin [2]